ABCL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Abcellera Biologics Inc (ABCL) is not a strong buy at this moment for a beginner investor with a long-term strategy. The technical analysis indicates a bearish trend, and there are no significant positive catalysts or trading signals to suggest immediate upside potential. While the company's financials show revenue growth, the persistent net losses and lack of recent news or influential trading activity make it prudent to hold off on buying for now.
The stock is in a bearish trend, with the MACD histogram below 0 and negatively contracting. RSI is at 27.797, indicating oversold conditions but not providing a clear signal. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support levels are at 2.854 and 2.598, with resistance at 3.683 and 3.939.
Revenue increased by 37.62% YoY in Q3 2025, indicating growth in the company's operations.
The company continues to report net losses (-$57.12M in Q3 2025), and there is no recent news or significant trading activity by insiders, hedge funds, or Congress. The stock has a bearish technical setup, and analyst predictions suggest a slight decline in the short term.
In Q3 2025, revenue increased by 37.62% YoY to $8.96M. However, the company reported a net loss of $57.12M, an 11.76% improvement YoY. EPS also improved to -0.19, up 11.76% YoY. Gross margin remained at 100%. Despite revenue growth, persistent losses weigh on the company's financial health.
No recent analyst ratings or price target changes available. Wall Street sentiment appears neutral to slightly bearish given the lack of positive catalysts and the company's ongoing losses.
